|Description||TC-E 5002 is a selective histone demethylase KDM2/7 subfamily inhibitor (IC50 = 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A, respectively) with antitumor activity. It suppresses growth of HeLa and KYSE-150 cancer cells in vitro.|
|Brife Description||histone demethylase KDM2/7 subfamily inhibitor|
|Purity||≥98% by HPLC|
|Synonyms||TC-E 5002; TC E 5002; TCE 5002; TCE-5002; TCE5002; TC-E-5002; N-(9-Cyclopropyl-1-oxononyl)-N-hydroxy-β-alanine|
KDM5-IN-1 is a potent and selective KDM5 inhibitor with modest cell activity (PC9 H3K4Me3 EC50 = 5.2 μM).
A novel histone lysine demethylase 4D (KDM4D) inhibitor (IC50= 0.41±0.03 μM)
CPI 4203 is a selective inhibitor of KDM5 demethylases structurally related to CPI 455.
DDP-38003 trihydrochloride is the trihydrochloride salt of DDP-38003 which is a potent, selective, oral bioavailable irreversible inhibitor of KDM1A.
(Z)-JIB-04 is a Z-isomer of JIB-04, which is a small-molecule histone demethylase inhibitor with antitumor activity. JIB-04 selectively inhibits tumor growth vi...
GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative...
GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just ...